• Users Online: 214
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
CASE REPORT
Year : 2015  |  Volume : 1  |  Issue : 1  |  Page : 33-34

Cutaneous histoplasmosis successfully treated with oral itraconazole monotherapy in a human immunodeficiency virus positive female


1 Department of Medicine, Antiretroviral Therapy Centre, Indira Gandhi Government Medical College, Nagpur, Maharashtra, India
2 Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, AVBR Hospital, Wardha, Maharashtra, India
3 Department of Dermatology, NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Nagpur, Maharashtra, India

Date of Web Publication1-Dec-2015

Correspondence Address:
Girish Ambade
Department of Medicine, Antiretroviral Therapy Centre, Indira Gandhi Government Medical College, Nagpur, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/WKMP-0110.170763

Rights and Permissions
  Abstract 

Histoplasmosis is a deep fungal infection with a worldwide distribution that can affect both immunocompromised and immunocompetant individuals. The majority of cases with cutaneous involvement also have systemic disease. Intravenous amphotericin is commonly employed for its treatment which is associated with significant side effects. We hereby report a of case cutaneous histoplasmosis in a human immunodeficiency virus (HIV) positive female who was treated successfully with oral itraconazole monotherapy along with anti-retroviral therapy. A 38-year-old HIV-positive female presented with multiple asymptomatic skin colored umbilicated papular eruptions over face, neck, trunk, and upper extremities of two and half months duration. She did not have any systemic complaints. Histopathology of the lesion showed a diffuse dermal granulomatous inflammation with 2–4 µ sized round organisms in macrophages with a clear halo suggestive of histoplasmosis. Her CD4 cell count was 38 cells/mm3. She was started on highly active antiretroviral therapy (tenofovir 300 mg OD, lamivudine 300 mg OD, and nevirapine 200 mg BID) along with cotrimoxazole prophylaxis. The patient was also prescribed oral itraconazole 100 mg twice daily. After 20 weeks of therapy, the patient showed complete resolution of lesions with minimal scarring. Histoplasmosis in retrovirus positive patient is frequently treated with intravenous amphotericin. Our patient responded to long-term itraconazole monotherapy.

Keywords: Acquired immunodeficiency syndrome, antifungal, disseminated histoplasmosis, efficacy, human immunodeficiency virus, Itraconazole


How to cite this article:
Ambade G, Madke B, Pande S. Cutaneous histoplasmosis successfully treated with oral itraconazole monotherapy in a human immunodeficiency virus positive female. Indian J Drugs Dermatol 2015;1:33-4

How to cite this URL:
Ambade G, Madke B, Pande S. Cutaneous histoplasmosis successfully treated with oral itraconazole monotherapy in a human immunodeficiency virus positive female. Indian J Drugs Dermatol [serial online] 2015 [cited 2024 Mar 19];1:33-4. Available from: https://www.ijdd.in/text.asp?2015/1/1/33/170763




  Introduction Top


Histoplasmosis is a thermal dimorphic intracellular fungal infection that can affect both immunocompromised and imunocompetent individuals.[1],[2] Histoplasmosis may occur in three forms: (i) Primary acute pulmonary form, (ii) chronic pulmonary and (iii) disseminated form. Disseminated form presenting with molluscum-like skin lesions is a characteristic feature of cutaneous histoplasmosis and is an acquired immunodeficiency syndrome (AIDS) defining illness.[3] Though amphotericin B is considered as a drug of choice, itraconazole is an effective alternate therapy which must be tried as a first line drug.


  Case Report Top


A 38-year-old widow presented with multiple asymptomatic skin colored umbilicated papular eruptions over face, neck, trunk, and upper extremities since two and half months duration. She had a history of pulmonary tuberculosis 10 years back and was adequately treated with standard anti-tubercular drugs. She did not have any systemic complaints.

On cutaneous examination, there were multiple discrete, skin colored umbilicated papules over face, neck, trunk, and both upper limbs [Figure 1]. Few of the lesions showed crusts. Mucosae were spared, and systemic examination revealed no abnormality. A differential diagnosis of Molluscum contagiosum, cutaneous cryptococcosis, cutaneous histoplasmosis, and penicilliosis was considered.
Figure 1: Skin lesions of cutaneous histoplasmosis (Pre-treatment)

Click here to view


Complete hemogram revealed anemia and leukopenia with erythrocyte sedimentation rate of 55 at the end of 1 h. Liver and renal functions tests were normal. Serologies for venereal disease research laboratory test and Australia antigen were negative. Rapid test for human immunodeficiency virus-1 was reactive. Chest X-ray chest and abdominal ultrasound revealed no abnormality. Histopathology of the lesion showed a diffuse granulomatous inflammation occupying the entire dermis with parasitized macrophages containing 2–4 µ sized round organisms with a clear halo suggestive of histoplasmosis. Her CD4 cell count was 38 cells/mm 3. She was diagnosed to have AIDS and was started on highly active antiretroviral therapy (tenofovir 300 mg OD, lamivudine 300 mg OD, and nevirapine 200 mg BID) along with cotrimoxazole prophylaxis. The patient was also prescribed oral itraconazole 100 mg twice daily. After 20 weeks of therapy, the patient showed complete resolution of lesions with minimal scarring [Figure 2].
Figure 2: Subsidence of cutaneous histoplasmosis after 5 months of oral itraconazole therapy

Click here to view



  Discussion Top


Amphotericin B has been considered as the treatment of choice for disseminated histoplasmosis in patients with AIDS. Prohibitive cost and nephrotoxicity are the major drawbacks of amphotericin B therapy. Oral antifungal agents would be welcome alternatives to standard treatment of disseminated histoplasmosis in less severe cases. In an open-label study of 59 patients done by Wheat et al., 50 patients with disseminated histoplasmosis responded to 12 weeks course of oral itraconazole.[4] Though oral itraconazole is not as a rapid acting agent as amphotericin B, it is well tolerated and lacks nephrotoxicity.[5]

Singhi et al. treated a case of disseminated primary cutaneous histoplasmosis in an imunocompetent female with itraconazole showing excellent results.[6] Itraconazole in oral capsule formulation needs gastric acid for absorption, and so are usually taken with food or acidic beverages. Immunocompromised patients with moderate disease can be treated with itraconazole monotherapy. An expert group recommended itraconazole 200 mg three times daily for 3 days followed by 200 mg twice daily for 12 months for immunocompromised hosts with pulmonary histoplasmosis or with the progressive or disseminated disease.[7]

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Adenis AA, Aznar C, Couppié P. Histoplasmosis in HIV-infected patients: A review of new developments and remaining gaps. Curr Trop Med Rep 2014;1:119-128.  Back to cited text no. 1
    
2.
Pal N, Adhikary M. Cutaneous histoplasmosis in a HIV seronegative patient. J Nat Sci Biol Med 2013;4:477-9.  Back to cited text no. 2
    
3.
Rosenberg JD, Scheinfeld NS. Cutaneous histoplasmosis in patients with acquired immunodeficiency syndrome. Cutis 2003;72:439-45.  Back to cited text no. 3
    
4.
Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995;98:336-42.  Back to cited text no. 4
    
5.
Kurowski R, Ostapchuk M. Overview of histoplasmosis. Am Fam Physician 2002;66:2247-52.  Back to cited text no. 5
    
6.
Singhi MK, Gupta L, Kacchawa D, Gupta D. Disseminated primary cutaneous histoplasmosis successfully treated with itraconazole. Indian J Dermatol Venereol Leprol 2003;69:405-7.  Back to cited text no. 6
[PUBMED]  Medknow Journal  
7.
Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011;183:96-128.  Back to cited text no. 7
[PUBMED]    


    Figures

  [Figure 1], [Figure 2]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Case Report
Discussion
References
Article Figures

 Article Access Statistics
    Viewed4876    
    Printed309    
    Emailed0    
    PDF Downloaded86    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]